On the bright sideA lot of things can be improved with the company, but let's focus on the bright side for the moment and turn the latest quarterly update into potential triggers that could generate a news release. The timings are my best guess.
Please observe that the headline of Anti-Cellulite is Antiviral... so it seems like text is missing in the latest NR.
If they nail everything on the list below I think the stock will trade between 1 and 2 dollars in the end of the year.
Q1
I expect the outcome of antiviral tests to be the next NR. If they don't want to provide feedback from BIO Partnering at JPM earlier in a separate NR.
The second news release could be the TFC-1067 deal. March could be a bit aggressive, but not impossible. Might slide into Q2.
Q2
Partnership for Animal Health (TFC-039)
Partnership for Anti-Aging
Partnership for Antiviral
Partnership for Anti-Cellulite
Q3/Q4
Clinical trial Anti-Aging
Clinical trial TFC-1394
Disclosure of new indication for TFC-039 (I guess obesity)
Would be great if they choose to run the Anti-Aging clinical trial head to head with Botox...